Loading clinical trials...
Loading clinical trials...
A First-in-human, Multicenter, Open-label, Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of Intravenously Administered ATOR-1015
Conditions
Interventions
ATOR-1015
Locations
5
Denmark
Phase 1 Unit, Department of Oncology, Rigshospitalet
Copenhagen, Denmark
Center for Cancer Research, Department of Oncology, Herlev Hospital
Herlev, Denmark
Kliniska Prövningsenheten, Kliniska Studier Sverige - Forum Söder, Skånes Universitetssjukhus
Lund, Sweden
Centrum för Kliniska Cancerstudier (CKC), Fas 1-enheten, Karolinska Universitetssjukhuset
Solna, Sweden
Onkologavdelningen, Akademiska Sjukhuset
Uppsala, Sweden
Start Date
January 30, 2019
Primary Completion Date
March 3, 2021
Completion Date
March 3, 2021
Last Updated
August 18, 2022
NCT05720117
NCT07213804
NCT06898450
NCT00026884
NCT07169851
NCT07159659
Lead Sponsor
Alligator Bioscience AB
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions